William T.C. Yuh, MD, MSEE
I chose to work in cancer care, because cancer is a major cause of morbidity and mortality, in addition to the tremendous cost and suffering to the society.
During the early development phase of the magnetic resonance (MR) contrast agents, I designed and conducted many clinical trials and facilitated the FDA approval of MR contrast agents, which have become essential components of current MR imaging examination. My recent research focuses on assessing tumor heterogeneity for early prediction of ultimate treatment outcomes for cancer and for the collateral circulation status for triaging therapy for acute stroke.
In my lifetime, I hope to see improvements in early diagnosis and early prediction of treatment failure to provide a window of opportunity to change treatment strategy. Additionally, I hope to see improvement to imaging-guided therapy and its ultimate treatment outcome.
Outside of work, I enjoy traveling to see the world and its people.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.